caa a22 4500 465789323 CHVBK 20180323112018.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216925 doi (NATIONALLICENCE)springer-10.1007/BF00216925 Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion [Elektronische Daten] [Carol Fabian, Roy Molina, Milan Slavik, Steve Dahlberg, Shankar Giri, Ronald Stephens] Summary: The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmarplantar erythrodysesthesia (PPE). PPE developed in 16/25 patients (exact 95% confidence interval of 42% -82%) with metastatic colon cancer enrolled in a phase II trial. In this trial, 5-FU was given continuously at a dose of 200 mg/m2/day until toxicity or progressive disease forced discontinuation. The first signs of the syndrome developed at a median of 2 months following infusion initiation and, unless treatment was interrupted, became progressively worse. The incidence of moderate to severe PPE was 71% in the 14 previously untreated patients (exact 95% confidence intervals of 42-92%). Seventy-eight percent of the responders in the no prior treatment group developed PPE. The incidence of moderate to severe PPE was only 27% in the 11 previously treated patients (exact 95% confidence intervals of 6-61%). The higher incidence of PPE in the previously untreated patients probably resulted from a longer total infusion time (median = 7.3 months) than the previously treated (median = 4.5 months). The longer infusion time in turn was a result of the higher response rates (64 vs 18%) in the previously untreated versus treated groups. Five previously untreated patients who developed PPE received 50 or 150 mg of pyridoxine/day when moderate PPE changes were noted. Reversal of PPE without interruption of the 5-FU was seen in 4/5 patients. Four of these patients who received pyridoxine had responded to 5-FU treatment. No adverse affect of pyridoxine on clinical response was noted. The five previously untreated patients who received pyridoxine for PPE continued 5-FU for a median of 6 months after development of the syndrome. The six previously untreated patients who did not receive pyridoxine when they developed PPE were able to continue 5-FU for a median of only 2.5 months after development of the syndrome. A similar number of clinical responders to 5-FU were present in both groups. Considering the high incidence of PPE and response in previously untreated colon cancer patients who receive protracted continuous 5-FU, prophylactic pyridoxine in conjunction with this treatment modality might be useful. Kluwer Academic Publishers, 1990 pyridoxine nationallicence palmar-plantar erythrodysesthesia nationallicence 5-FU nationallicence Fabian Carol University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut Molina Roy University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut Slavik Milan University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut Dahlberg Steve Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, 98104, Seattle, Washington, USA aut Giri Shankar University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut Stephens Ronald University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 57-63 0167-6997 8:1<57 1990 8 10637 https://doi.org/10.1007/BF00216925 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216925 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fabian Carol University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut NATIONALLICENCE 700 1- Molina Roy University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut NATIONALLICENCE 700 1- Slavik Milan University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut NATIONALLICENCE 700 1- Dahlberg Steve Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, 98104, Seattle, Washington, USA aut NATIONALLICENCE 700 1- Giri Shankar University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut NATIONALLICENCE 700 1- Stephens Ronald University of Kansas Medical Center, Division of Clinical Oncology, Division of Radiation Oncology, 66103, Kansas City, Kansas, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 57-63 0167-6997 8:1<57 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer